Walrabenstein et al. designed three 16-week observer-blind randomized clinical trials (RCTs) with a waiting-list control group for patients with RA with low to moderate disease activity (2.6 ≤ Disease Activity Score [DAS28] ≤ 5.1, RCT 1, n = 80), for patients at risk for RA, defined by anti-citrullinated protein antibody (ACPA)-positive arthralgia (RCT 2, n = 16) and for patients with metabolic syndrome and osteoarthritis in the knee and/or hip (RCT 3, n = 80). The gene discussed is PRTN3; the disease is rheumatoid arthritis.